BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

1/2期 提前终止 NCT03695250

摘要

This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving BMS-986205 and nivolumab may work better in treating patients with liver cancer.

Adverse Events (AE)

Up to 2 years. · participants

Objective Response Rate (ORR)

Up to approximately 2 years, 1 month. · percentage of participans

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
• Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
• A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)
• Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis — National Cancer Institute (NCI)

全部试验